Randomized Phase II Trial Comparing Sequential First-line Sunitinib and Second-line Avelumab vs First-line Avelumab and Second-line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial. Hoosier Cancer Research Network GU15-223
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Feb 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SUAVE Trial
- 28 Jan 2019 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2018.
- 28 Jan 2019 Planned initiation date changed from 1 Jul 2017 to 23 May 2017.
- 28 Jan 2019 Status changed from active, no longer recruiting to withdrawn prior to enrolment.